Parallax Volatility Advisers’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,400
Closed -$274K 2222
2023
Q3
$274K Buy
+1,400
New +$287K ﹤0.01% 1744
2023
Q2
Sell
-26,000
Closed -$5.25M 2475
2023
Q1
$5.25M Buy
+26,000
New +$5.89M 0.01% 838
2022
Q4
Sell
-100
Closed -$20K 2937
2022
Q3
$20K Buy
+100
New +$21.6K ﹤0.01% 2744
2022
Q2
Sell
-100
Closed -$28K 2946
2022
Q1
$28K Buy
+100
New +$30.8K ﹤0.01% 2558
2021
Q4
Sell
-10,000
Closed -$4.13M 3070
2021
Q3
$4.13M Buy
+10,000
New +$4.15M ﹤0.01% 1322
2021
Q1
Sell
-500
Closed -$125K 3296
2020
Q4
$125K Sell
500
-151,600
-100% -$36.1M ﹤0.01% 2896
2020
Q3
$34.4M Buy
+152,100
New +$31.6M 0.03% 527

Other funds holding CRL

Parallax Volatility Advisers's CRL Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 80 shares — an estimated $19.1K sold.

Parallax Volatility Advisers first reported a position in CRL in Q1 2019 and held it in 6 quarters. The position peaked at $8.24M in Q4 2020. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Parallax Volatility Advisers reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 80 Charles River Laboratories shares in Q1 2024, an estimated $19.1K.
  • Parallax Volatility Advisers first reported a position in Charles River Laboratories in Q1 2019 and held it in 6 quarters.
  • Parallax Volatility Advisers's Charles River Laboratories position peaked at $8.24M in Q4 2020.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.